MD Anderson Cancer Center
The University of Texas
Houston, TX
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
Maintenance Trials
Only view trials that include maintenance therapy.
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
SUCCESSOR-1
Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared to Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
- CELMoD
- Randomization
- Phase 3
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
EXCALIBER - Maintenance
Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
- CELMoD
- Post-Autologous Stem Cell Transplant
- Randomization
- Phase 3
Accepting patients
CA088-1005
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
- CAR T Cell
- CELMoD
- GPRC5D
- Phase 1
Accepting patients
Belantamab Mafadotin Maintenance Therapy
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1
Accepting patients
MagnetisMM-4
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
- Bispecific Antibody
- Gamma-Secretase Inhibitor
- BCMA
- Phase 1/2
Accepting patients
LINKER-MM4
Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1/2
Accepting patients
Pre and Post Transplant Elranatamab
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
- Autologous Stem Cell Transplant
- BCMA
- CD3
- Phase 2
Not yet accepting
MajesTEC-7
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
- Has results
Not yet accepting
iMMAGINE-1
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- BCMA
- Phase 2
- Has results
1 hidden based on your filters. Show All